Achondroplasia Epidemiology Forecast 2025-2034

Achondroplasia, a rare genetic condition, is the most prevalent primary skeletal dysplasia in humans. More than 90% of cases of dwarfism, or disproportionate short stature, are caused by this type of dysplasia. Every year, between 1 in 20,000 to 30,000 live births result in achondroplasia. According to estimates, the prevalence is between 1 and 9 people per 100,000 of the general population worldwide.

Achondroplasia Epidemiology Forecast Report Coverage

The “Achondroplasia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of achondroplasia. It projects the future incidence and prevalence rates of achondroplasia across various populations. The study covers age, gender, and type as major determinants of the achondroplasia-affected population. The report highlights patterns in the prevalence of achondroplasia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of achondroplasia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Achondroplasia Disease Overview

Achondroplasia is a hereditary condition that mainly affects the long bones and results in dwarfism because of aberrant bone growth. Short stature with disproportionate limb size and inhibited cartilage development are the results of a mutation in the FGFR3 gene. A big head, a noticeable forehead, and a curvy spine are typical characteristics. Although they may suffer from health issues like spinal stenosis or breathing problems, people with skeletal abnormalities usually have normal intelligence and life expectancy.

Achondroplasia: Treatment Overview

Rather than curing achondroplasia, treatment aims to improve quality of life and manage symptoms. While vosoritide, a more recent FDA-approved medication, can slightly increase children's bone growth, growth hormone therapy may occasionally result in modest height gains. Severe bone deformities can be addressed with the aid of orthopaedic interventions, such as limb lengthening surgery. Physical therapy, weight control, and observation for complications such as respiratory problems and spinal stenosis are all components of supportive care.

Epidemiology

The achondroplasia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for achondroplasia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for achondroplasia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Adult height in individuals with achondroplasia ranges from 42 to 56 inches. This condition results in shorter, abnormally shaped bones and a slower rate of bone growth in the growth plate cartilage. Furthermore, neurological impairment affects 20 to 50% of newborns with the condition.
• An article by Johns Hopkins University revealed that developmental milestones are delayed in achondroplasia. For example, walking may start between 18 and 24 months of age rather than around 12 months.
• A study reported that about 80% of patients develop achondroplasia because of a spontaneous alteration in the FGFR3 gene, while the remaining 20% inherit it from a parent.
• According to a review study, achondroplasia affects a person's height. On average, men with the condition are 4 feet, 4 inches tall, and women are 4 feet, 1 inch tall.

Country-wise Achondroplasia Epidemiology

The achondroplasia epidemiology data and findings for the United States, Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of achondroplasia varies between countries, owing to the differences in factors such as socioeconomic disparities that impact early diagnosis and specialized care availability, genetic factors, and others. According to the systematic review, there are 4.00 cases of achondroplasia for every 100,000 live births in North America. Achondroplasia prevalence in the United States was found to be between 0.36 and 0.60 per 10,000 live births (or 3.6 and 6.0 per 100,000 live births) in a population-based epidemiological study.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of achondroplasia based on several factors.
• Achondroplasia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of achondroplasia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of achondroplasia epidemiology in the 8 major markets?
• What will be the total number of patients with achondroplasia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of achondroplasia in the 8 major markets in the historical period?
• Which country will have the highest number of achondroplasia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of achondroplasia during the forecast period of 2025-2034?
• What are the currently available treatments for achondroplasia?
• What are the disease risks, signs, symptoms, and unmet needs of achondroplasia?

This product will be delivered within 3-5 business days.